Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pandemic influenza vaccine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Pandemic influenza vaccine | BIOLOGICAL | - |
Inclusion Criteria: * Healthy Subjects 18 years of age who signed the informed consent Exclusion Criteria: * Receipt of another investigational agent within 4 weeks * Receipt of influenza vaccination for current season 2006/2007. * any acute disease or infection, history of neurological symptoms ...
Pandemic influenza vaccine is used for influenza, specifically to provide immunity against pandemic influenza strains. It is an investigational vaccine being developed by Novartis AG for the prevention of influenza infection in adult and elderly populations.
Pandemic influenza vaccine is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The vaccine is currently in clinical development for the prevention of influenza.
Pandemic influenza vaccine is in Phase 3 clinical development. It is an investigational vaccine, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, but the vaccine remains under investigation.
Pandemic influenza vaccine has one completed Phase 3 clinical trial, NCT00434733, which evaluated the immunogenicity, safety, and tolerability of two doses of FLUAD-H5N1 influenza vaccine in adult and elderly subjects. The trial enrolled 4,400 participants in Poland.
Yes, Pandemic influenza vaccine is also known as FLUAD-H5N1. The Phase 3 clinical trial NCT00434733 specifically tested FLUAD-H5N1, which is the pandemic influenza vaccine formulation being developed by Novartis AG for influenza prevention.